The Ministry of Health’s Commission on Drug Lists has officially approved the addition of the antibiotic ceftobiprole medocaril and the medication goflikicept to the list of vital and essential drugs (VED). The decision was made at a meeting on November 7, 2024. The application for the inclusion of the drug anagrelide, used to reduce platelets, was rejected by the commission.
The commission recommends including ceftobiprole medocaril.in the VED list. The registration certificate is maintained by Lancet JSC, operating under the trade name “Zeftera,” while the final dosage form is produced by the esteemed Japanese manufacturer, Nipro Pharma Corporation. The drug was registered in April 2024. It was developed by the biopharmaceutical company Basilea, headquartered in Switzerland. Its website states that Lancet supplies the drug to Eurasian countries.